Member Info for Kaeren

@Stokey12 , way back when I posted something that about SeaRose that said scope of work would either be x or x. From memory neither were six months.

As no contract has yet been announced for SeaRose or another FPSO it's a wait and see . Let's hope it's two that would sort 2024 numbers .

Https://www.linkedin.com/posts/david-honeyman-480a34b_with-the-continual-build-up-of-work-in-our-activity-7118270995911598080-eb9q?utm_source=share&utm_medium=member_android

That's nice , with a 15 % spread. Good luck.

I was not aware it was in a programme to screen. I was aware it was commercially available and fully reimbursable. So whilst playing the old news , no news fiddle , rest assured I shall post anything I consider relevant to something I'm invested in. Those not invested might object... just saying.

The test is being commercialised in the US as part of a 💥programme💥 to screen men for prostate cancer, either with an elevated PSA result or where prostate cancer must be ruled out.

University of Pennsylvania Hospital professor of surgery and Penn Presbyterian Medical Center urology section chief Phillip Pierorazio said: “Although the traditional PSA has demonstrated clinical utility in prostate cancer screening and monitoring, it also has limitations that are well-described"

“A more sensitive and specific test would have the potential to increase diagnostic accuracy and address some of the current challenges with prostate cancer screening"

https://www.nsmedicaldevices.com/news/oxford-biodynamics-episwitch-pse-test-in-us/

Hi Scaffman, I posted it as a positive , if I thought we weren't getting the required finance I'd be long gone . I rate Charles , although I don't put Harl in the same risk category at all.

Don't bite the bait. 2.am a good time if you can't see the wood for the trees.

Think about who holds and is nervous and who is on a permanent wind up ...

It's like bloody 'miss you nights ' on here.

Great, thx LSE03

Let's have a bun fight .

You obviously haven't had much luck on aim, all your posts are negative, what if , why , not much publicity. It has had loads , it's just out the traps , it's life changing , got clearance in two months instead of two years. Try some wine instead of having a whine.

What do you want to hear , write to the company if you are concerned. We've just had two blockbuster RNS's and I'm more then happy. Very undervalued

for the potential.. Too small for Nasdaq , it will come, we already have funds invested.

One of those opportunities that very rarely arise.

Ready steady ..

https://twitter.com/that_stocks_guy/status/1712027743603298606?t=Wc49tOAAJ1bAqQkBrBMxgw&s=19

Oops little ones wanting to press post message. I see those with alternative motives have arrived back. Have fun.

It will work by word of mouth, already seen articles by top urologists and surgeons in US hospitals, the very folks who will be recommending these tests.

1

.the

01440 269491

Oh good , more inf on your response 👏

That was not something I addressed and therefore was not answered.

Imo, I see absolutely no reason why they wouldn't. It will ultimately be much cheaper then paying for biopsies and Mri scans , it will dramatically narrow the cohort of patients requiring further investigation and unnecessary medical intervention.

This will gain momentum very fast and I have no doubt those worried about sp movements of a penny or two won't be worried shortly. News of overwhelming response to test live could drop anytime.

Dear Kaeren,

Thank you for your enquiry about communications and apologies for the delay in our response.

The news about the launch of the PSE test and reimbursement code has been issued widely to media in the UK and the US and was covered by several mainstream newspapers/websites including The Times, The Daily Mail (mailonline in Money and Health sections) and the Sunday Express, some of which included content from interviews with OBD team members. Just as healthcare professionals and patient advocacy groups will want to look into the test and its features, so will the healthcare press. We anticipate that the test is likely to gain more traction with both the mainstream and healthcare media as more physicians order it, see patients benefit from it and in turn talk about it. We are continuing to encourage this to happen.

Thanks again for your interest and support,

With best wishes,

Oxford BioDynamics

Am sure this has been posted before, I don't read board everyday.

It would be really worthwhile if some could get in touch with producers, the resident doc on the orogramme, so they could cover again as it is now live.

Programme from June.

https://twitter.com/OxBioDynamics/status/1669730142485200897

Https://www.cornwalllive.com/news/cornwall-news/isles-scilly-ferry-rival-fast-8817150

Hi @Stokey12 that's ROI €250.00 Dublin address. The company confirmed to me the 16th , I asked a series of questions, this was one of them.

THE 16TH .

Yes Xenor my oversight and a large one you are correct. Right now and is sad to see there are undoubtedly some selling at a loss and others selling still in profit but substantially less then several months ago. It all boils down imo as to whether you believe a finance deal will be delivered. Personally I do and therefore don't focus on intraday price movements.

I agree with Xenor in regards to lack of financial stability ( the deal) preventing some contracts reaching successful conclusion. If you have to forward schedule major works, the minimum level of confidence in your chosen supplier has to be that they will still be fully functioning and able to complete set work. I also believe the delay is down to the govt departments involved and cannot be levelled at JW directly.

I'm sure he wants/needs this resolved as much if not more then shareholders.

Yes Broomtree a counterbalance ASAP on the board who can tailor the direction of travel and keep all the players JW included firmly in their lane.